commercial expansion

Palantir surged 23% in one month on 70% revenue growth and 137% U.S. commercial expansion, but extreme P/E ratio of 255 raises valuation concerns despite solid fundamentals.

Palantir delivers 70% revenue growth with rule of 40 score of 127%, signaling potential bargain despite elevated valuation.

Palantir surged 2,200% since 2023 with 70% revenue growth, but 116x forward earnings valuation—5x Nvidia—may already price in years of gains.

Microbot Medical confirms uninterrupted USA and Israel operations amid geopolitical tensions, accelerating LIBERTY robotic system expansion with planned April 2026 commercial launch.

Palantir surged 11% on strong earnings showing 70% revenue growth, but 80x sales valuation leaves little room for error. Analysts recommend waiting for better entry points.

Palantir reports 70% revenue growth and 79% EPS growth with 137% commercial surge, though 100x P/E valuation leaves limited room for error amid recent 26% pullback.

Orange Bank & Trust promotes Joseph Ruhl to Senior Executive Vice President, recognizing his nine-year track record expanding deposits and business development in Westchester County and Lower Hudson Valley markets.

Harrow Health will release 2025 financial results March 2, 2026, reaffirming $270-$280 million revenue guidance and highlighting its expanding pharmaceutical portfolio.

Palantir's stock surged over 1,300% since its 2020 IPO, with a $10,000 investment growing to $142,820. AI adoption and sector expansion drive continued analyst optimism.